跳至主要内容
临床试验/EUCTR2009-012115-18-NL
EUCTR2009-012115-18-NL进行中(未招募)不适用

Primovist enhanced MRI for the detection and evaluation of focal liver lesions - PRIDE-study

MC Utrecht0 个研究点开始时间: 2010年3月3日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - age > 18 years
  • - suspicion of focal liver lesions, both benign and/or malignant:
  • - Haemangioma
  • - Focal Nodular Hyperplasia
  • - Cystadenoma
  • - Metastasis
  • - Hepatocellular Carcinoma (HCC)
  • - Cholangiocarcinoma
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - primary clinical query on the liver MRI chart: liver cirrhosis, hepatitis, steatosis, or liver abscess, or any other liver disease not defined as focal disease.
  • - previous liver surgery
  • - a pacemaker
  • - severe renal disease (creatinin clearance <30ml/min or haemodialysis is necessary)
  • - administration of a liver specific contrast agent within 2 weeks prior to the first MRI with Primovist.
  • - claustrophobia
  • - hypersensitivity to the active substances or any of the recipients of Gd-EOB-DTPA contrast:
  • - previous reaction to contrast media
  • - history of bronchial asthma
  • - history of allergic disorders causing anaphylactic shock
  • - caution should be exercised in patients with clinically severe cardiovascular disease. Myocardial infarction, uncontrolled hypertension, instable angina pectoris, congestive heart failure, uncontrolled arrhythmia’s requiring medication
  • - pregnancy or lactating women (in case of uncertainty, a pregnancy test will be performed)
  • - treatment with rifampicin (inhibitor of Gd-EOB-DTPA uptake)

研究者

发起方
MC Utrecht

相似试验